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Abstract  
Recently, we reported an aptamer-based, highly multiplexed assay 
for the purpose of biomarker identification. To enable seamless transition 
from highly multiplexed biomarker discovery assays to a format suitable 
and convenient for diagnostic and life-science applications, we developed 
a streamlined, plate-based version of the assay. The plate-based version of 
the assay is robust, sensitive (sub-picomolar), rapid, can be highly 
multiplexed (up to 200 analytes), and fully automated.  We demonstrate that 
quantification by microarray-based hybridization, Luminex bead-based 
methods, and qPCR are each compatible with our platform, further 
expanding the breadth of proteomic applications for a wide user 
community. 
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Introduction 
 
Initial proteomic analyses using 2D gels were carried out in the  1970’s [1].  
Due to significant technical challenges [2], the promise of proteomics is only now 
being realized in biomarker discovery, life science research, pharmaceutical 
research and development, and medical diagnostics. We developed an aptamer-
based multiplexed proteomic technology for biomarker discovery (the SOMAscan 
platform) and have successfully applied this technology to discover biomarker 
signatures in clinical studies of human diseases [3,4].  For high-content 
biomarker discovery, this technology was implemented with a bead-based assay 
on an automated robotic platform [5]. This discovery assay is highly multiplexed 
(>800 analytes), sensitive (sub-picomolar), reproducible, and quantitative [3].  
Here we present a streamlined microtiter plate-based version of our proteomics 
discovery assay to provide a rapid, efficient and seamless transition from 
SOMAScan-developed biomarker panels identification to [3,4] to actual in vitro 
diagnostics small plex panels and specialized proteomics measurements that 
facilitate clinical drug development. We term this streamlined aptamer-based 
assay format a SOMAPanel. 
 
Results  
 
Principles of SOMAScan and SOMAPanel assays: At the core of the assay is 
an analyte capture reagent that consists of a fully synthetic aptamer coupled to a 
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biotin moiety through a photocleavable linker (Figure 1A). The biotin moiety 
permits binding to the streptavidin supports used for immobilization and wash 
steps, while the photocleavable linker permits release of the aptamer into 
solution after washing. A Cy3 fluorophore built into the capture reagents used in 
this study permits quantification by means of commercially available slide-based 
microarray hybridization systems, but is not required for all formats of the assay. 
  We note that while any aptamer with sufficient affinity and slow 
dissociation rate could be used in the proceeding manner, the aptamer reagents 
used in our published work are single-stranded DNA and bear dU residues each 
uniformly functionalized at the 5-position (e.g. benzyl, 2-napthyl, or 3-indolyl-
carboxamide). These modified nucleotides greatly improve nuclease resistance, 
affinity, and selection success rate [6]. Such specialized aptamers are termed 
“SOMAmers” (Slow Off-rate Modified Aptamer). Here we use the generic term 
“aptamers”, however, the data presented here was generated with SOMAmers 
exclusively. It should also be noted that in this work “PB-aptamer” refers to the 
photocleavable biotin aptamer capture reagent in its entirety, while “aptamer” 
refers to the aptamer component alone. 
 The assays themselves consist of a binding step in which PB-aptamers 
and analytes are equilibrated in solution (Figure 1B Panel 1), followed by 
immobilization of all PB-aptamers on a streptavidin-substituted support (Figure 
1B Panel 2, “Catch-1”). Subsequent washes remove proteins that are not stably 
complexed with PB-aptamers. Proteins immobilized through interaction with 
bound PB-aptamers are biotinylated with an amine-reactive biotinylation reagent 
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(N-hydroxysuccinimide –PEO4-biotin). After further washes, the entire aptamer 
population, including analyte-aptamer complexes, is released into solution via 
long-wave ultraviolet light-catalyzed cleavage of the biotin-bearing 
photocleavable linker (Figure 1B Panel 3). The biotinylated analyte-aptamer 
complexes are then selectively captured on another streptavidin support (Figure 
1B Panel 4, “Catch-2”) and the remaining, non-complexed aptamers are washed 
away. Finally, analyte-bound aptamers are eluted by disrupting the affinity 
interaction (Figure 1B Panel 5). Eluted aptamers are surrogates for analyte 
concentrations that can be quantified by standard DNA-quantification methods, 
for example, qPCR, or hybridization to microarrays (Figure 1B Panel 6).   
To develop the plate-based SOMAPanel assay, a model multiplex 
consisting of nine PB-aptamers specific for the proteins IL-8, tPA, resistin, MIP-4, 
MMP-7, MMP-9, RANTES, MCP-1, and Lipocalin 2, and twenty control PB-
aptamers, was assembled. These target analytes represent three broad ranges 
of abundance in plasma or serum, and their SOMAmer capture reagents were 
demonstrated as specific for their respective analytes by pull-down assay 
(Supplemental Figure 1).  The twenty control PB-aptamers have no cognate 
analyte in serum or plasma and were used to monitor non-specific aptamer 
signaling.  
 
Features of the plate-based SOMAPanel assay: Substitution of streptavidin 
plates for streptavidin-agarose beads and magnetic streptavidin beads eliminates 
both vacuum filtration and magnetic separation from the assay protocol. In 
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manual form, the assay becomes a “wash and dump” procedure that is 
reminiscent of an ELISA-based assay. The processing time is roughly 70 
minutes. A diagram of the assay steps is shown in Figure 2A.  
Dose-response curves with purified analytes generated in the plate-based 
assay performed manually are shown in Figure 2B. This 9-plex measurement 
compared assay response to increasing spiked-in analyte concentration as a 
function of PB-aptamer concentration in the presence of plasma. In general, little 
sensitivity is gained by elevated aptamer concentrations. We have chosen an 
intermediate concentration, 0.5 nM in each PB-aptamer, for the work shown 
here, though it is apparent from the curves that more or less PB-aptamer can be 
used in this particular analyte panel without significant penalty.  
Semi-automation of the plate-based assay: It was anticipated that the “wash 
and dump” nature of the plate-based assay would permit automation using 
commercially available, relatively low-cost instrumentation intended for ELISA. 
The nature of the assay suggested that the additional capability of multiple 
reagent addition would permit near-complete automation. The commercially 
available BioTek EL406 was selected for this capacity.  In addition to its 
conventional plate-washing capability, the EL406 supports addition of up to six 
different reagents, which is the number of solutions used in this assay.  
Adaptation of the manual protocol for use with the EL406 was 
straightforward, and measurement of lower limits of quantification (LLOQ) in a 9-
plex, semi-automated, plate-based assay revealed little loss in sensitivity or 
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stability relative to the bead-based SOMAScan assay (Figure 3 and 
supplemental materials, compare left and right panels). 
The semi-automated, plate-based assay protocol proved considerably 
more rapid and convenient than the semi-automated bead-based assay. The 
post-equilibration processing time was reduced from one hundred fifty minutes to 
fifty minutes, thus allowing for greater (circa 4-fold) throughput. Hands-on 
operations for the semi-automated assay are limited to movement of plates from 
plate washer to UV lamp and back; and transfer of samples from one plate to 
another after photocleavage. Little attendance is required other than for these 
steps. Preparation and pipetting of beads is eliminated. A summary of these 
differences is presented in Table 1. 
  Nucleic acid quantification schemes: The bead-based assay and 
plate-based experiments shown up to this point use a nucleic acid quantification 
system based on hybridization to printed microarrays from Agilent to quantify 
aptamers in the final assay eluate. This system has the capacity to quantitatively 
measure more than 3000 analytes per sample, and even higher levels of 
multiplexing are certainly possible. It has proven sensitive and convenient for 
very highly multiplexed biomarker discovery applications.  However, many labs 
have invested in other potentially suitable hybridization-based nucleic acid 
quantification instrumentation. Hence, we compared an alternative bead-based 
nucleic acid quantification platform with Agilent microarrays with respect to 
compatibility with our aptamer-based multiplex assay.  
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 We measured limits of quantification of 9 analytes in multiplex format, in 
exactly the same manner as in Figure 3.  We split the final eluates into two parts 
and independently determined limits of quantification using Agilent microarrays 
and the Luminex bead-based system as a final readout (Table 2). We found that 
sensitivity and dynamic ranges are roughly comparable between the two 
platforms, although Luminex was slightly less sensitive than Agilent (Table 2, 
compare columns 2 and 3), and exhibited slightly elevated upper limits of 
quantification (Table 2, compare columns 4 and 5).  
 Our biomarker discovery efforts have revealed that analyte concentration 
differences that distinguish case from control populations are often subtle. 
Indeed, we have discovered useful biomarkers that differ by as little as twenty 
percent between case and control [4]. To determine whether the plate-based 
assay in combination with a Luminex bead-based nucleic acid readout is suitable 
for measurements involving such subtle analyte concentration differences in the 
region of endogenous levels, we spiked in analytes in 20% increments, in 
quintuplicate, in the regions of analyte signal (and presumably, endogenous 
analyte concentrations) previously measured in serum titrations performed in the 
plate-based format (data not shown).  It should be noted that listed analyte 
concentrations are nominal, based on protein mass as noted by the manufacturer 
without reference to purity, and hence cannot be used as standards to infer 
actual endogenous concentrations. 
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We find that even at these low levels of signal, subtle changes in concentration 
can be measured with good precision (Figure 4).  The average CV for all 
analytes was 6.1%, with linear responses in the ranges tested. 
  .   
Validating the plate-based front end with alternative back-end readouts:  
We wished to determine whether the plate-based assay, in combination with an 
alternative nucleic acid (aptamer) readout, is sufficiently sensitive and robust to 
separate case and control populations within a clinical sample set, which is one 
commercial diagnostic application anticipated for this assay. To this end we 
performed an experiment in which various analytes were spiked at levels 
comparable to those we have encountered in the course of biomarker discovery 
into a collection of individual serum samples, effectively creating a mock disease 
signature in a population of samples. The ability to distinguish differential 
expression of analytes, both up and down with respect to the control population, 
forms a practical criterion for the adequacy of the assay to discern target 
responses against the backdrop of individual sample variance.  
Serum samples from twenty-four healthy controls were used to create a 
protein signature with both “up-” and “down-regulated” analytes.  Two aliquots of 
each sample were used to produce a separate control and a case population by 
adding analytes to each group.  Spikes into the twenty-four samples comprising 
the control group will result in “down-regulated” measurements in the case 
population while spikes into the case population will result in “up-regulation”.   We 
spiked three analytes into the control samples (tPA, MMP-9, and Lipocalin 2), 
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and four analytes in the case samples (IL-8, MCP-1, resistin and RANTES).  The 
model multiplex assay was used to explore differential expression in this set of 
mock case and control samples.   
The results are presented in Figure 5. Cumulative distribution functions 
(CDFs) were constructed separately for the case and control populations for 
each of the nine analytes.  The three analytes spiked into the control group result 
in clearly identified “down-regulation”, while the four analytes spiked into the case 
group appear as “up-regulation” in our mock protein signature.  The two analytes, 
for which no spikes were added, MIP-4, and MMP-7, display no differential 
expression, attesting to the specificity of the aptamer assay. The magnitudes of 
the spiked proteins were relatively small to result in mostly overlapping 
distributions between case and control populations yet with discernable 
differences that are comparable to those observed in actual case/control 
proteomic studies [4]. The plate-based aptamer assay performed well in this 
model multiplex diagnostic application. 
 
Discussion 
   
We developed a streamlined multiplexed aptamer-based assay that is 
robust, sensitive, and quantitative.  It is designed to enable the translation of 
discovery biomarker panels into robust diagnostic products and to facilitate use 
of small panels during clinical development of drugs.  The ease of use of the 
assay is roughly comparable to that of single-analyte ELISA. The assay is easily 
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and inexpensively automated.  Throughput can be made relatively high and 
sample volumes are quite small (~15 µL). Equipment and materials for the assay 
are commercially available from several sources. The final readout can be made 
inexpensive and scaled according to analyte number by use of a commercially 
available, bead-based nucleic acid quantification system. 
  Recently, we have identified several biomarker panels with potential 
diagnostic applications for chronic kidney disease [3], lung cancer [4], 
mesothelioma, and pancreatic cancer [in preparation]. Use of these biomarker 
panels in diagnostic applications will require the measurement of perhaps 9-15 
analytes in a single sample. The streamlined assay presented here permits 
seamless transition from such biomarker panels identified in SOMAScan-based 
studies to actual diagnostic applications.  We have demonstrated such utility by 
spiking analytes into a sample population to produce typical differential 
expression observed in proteomic studies of case/control groups. 
 We have found that the bead-based nucleic acid quantification system 
from Luminex can be used for final readout without significant performance 
penalty. This is advantageous in that it permits scaling of the final readout to the 
number of analytes to be measured.  As such, the assay can be made more 
economical for applications involving specific small analyte panels.  Moreover, 
the demonstration that several readout platforms may be used will render the 
aptamer-based assay easily accessible to groups and institutions that already 
possess other gene expression measurement platforms. 
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 We have also explored the use of real-time quantitative PCR (qPCR) as a 
back-end read-out for the plate- and bead-based assays. As might be expected, 
qPCR is exquisitely sensitive, and can be made reproducible and quantitative 
with appropriate optimization (supplemental Figure 3 and data not shown). We 
conclude that qPCR is a viable back-end readout option for the aptamer-based 
assay presented here, and is certainly suitable for experimentation as well as 
routine assays in labs that possess the necessary equipment.   
We have only briefly explored the upper limits of multiplex capacity of the 
plate-based assay but have verified that at least 60 analytes, selected from a 
lung cancer panel identified as biomarkers in an 836-plex SOMAScan assay, 
may be multiplexed without optimization (Supplemental Figure 4) 
The use of aptamers as capture reagents carries advantages over 
traditional immunoassays developed with antibody sandwiches. The synthetic 
nature of aptamers ensures uniformity and availability. Customization of the 
affinity reagent is routine, relying only on the availability of the appropriate 
phosphoramidites. Aptamers are chemically stable and resistant to freeze-thaw 
cycles as well as heat denaturation. Custom generation of aptamers to protein 
targets is generally rapid and inexpensive compared to antibodies. The intrinsic 
limitations of multiplex capabilities of antibodies are greatly diminished with 
aptamers.  To date, we have successfully multiplexed up to 836 aptamer 
measurements in a single 15 µL sample and do not anticipate an upper limit on 
multiplexing.  
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Materials and Methods 
 
Purchased reagents: HEPES, NaCl, KCl, EDTA, EGTA, MgCl2 and Tween-20 
were purchased from Fisher Biosciences. Dextran sulfate sodium salt (DxSO4), 
nominally 8000 molecular weight, was purchased from AIC and dialyzed against 
deionized water for at least 20 hours with one exchange. KOD EX DNA 
polymerase was purchased from VWR. Tetramethylammonium chloride and 
CAPSO were purchased from Sigma-Aldrich and streptavidin-phycoerythrin 
(SAPE) were purchased from Moss Inc. 4-(2-Aminoethyl)-
benzenesulfonylfluoride hydrochloride (AEBSF) was purchased from Gold 
Biotechnology. Streptavidin-coated 96-well plates were purchased from Thermo 
Scientific (Pierce Streptavidin Coated Plates HBC, clear, 96-well, product number 
15500 or 15501). NHS-PEO4-biotin was purchased from Thermo Scientific (EZ-
Link NHS-PEO4-Biotin, product number 21329), dissolved in anhydrous DMSO, 
and stored frozen in single-use aliquots. IL-8, MIP-4, Lipocalin-2, RANTES, 
MMP-7, and MMP-9 were purchased from R&D Systems. Resistin and MCP-1 
were purchased from PeproTech, and tPA was purchased from VWR. 
Nucleic acids: Conventional (including amine- and biotin-substituted) 
oligodeoxynucleotides were purchased from Integrated DNA Technologies (IDT).  
Z-Block is a single-stranded oligodeoxynucleotide of sequence 5’- (AC-BnBn)7-
AC-3’, where Bn indicates a benzyl-substituted deoxyuridine residue. Z-block 
was synthesized in-house, using conventional phosphoramidite chemistry. 
SOMAmer capture reagents were synthesized in-house by conventional 
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phosphoramidite chemistry, and purified on a 21.5 X 75 mm PRP-3 column, 
operating at 80°C on a Waters Autopurification 2767  system (or Waters 600 
series semi-automated system), using a timberline TL-600 or TL-150 heater and 
a gradient of triethylammonium bicarbonate (TEAB) / ACN to elute product.  
Detection was performed at 260 nm and fractions were collected across the main 
peak prior to pooling best fractions.   
 
Buffers: Buffer SB18 is composed of 40 mM HEPES, 101 mM NaCl, 5 mM KCl, 
5 mM MgCl2, and 0.05% (v/v) Tween 20 adjusted to pH 7.5 with NaOH.  Buffer 
SB17 is SB18 supplemented with 1 mM EDTA.  Buffer PB1 is composed of 10 
mM HEPES, 101 mM NaCl, 5 mM KCl, 5 mM MgCl2, 1 mM trisodium EDTA and 
0.05% Tween-20 adjusted to pH 7.5 with NaOH. CAPSO elution buffer consists 
of 100 mM CAPSO pH 10.0 and 1M NaCl. Neutralization buffer consists of 500 
mM HEPES, 500 mM HCl, and 0.05% w/v Tween-20.  Agilent Hybridization 
Buffer is a proprietary formulation that is supplied as part of a kit (Oligo 
aCGH/ChIP-on-chip Hybridization Kit). Agilent Wash Buffer 1 is a proprietary 
formulation (Oligo aCGH/ChIP-on-chip Wash Buffer 1, Agilent). Agilent Wash 
Buffer 2 is a proprietary formulation (Oligo aCGH/ChIP-on-chip Wash Buffer 2, 
Agilent).  TMAC hybridization solution consists of 4.5 M tetramethylammonium 
chloride, 6 mM trisodium EDTA, 75 mM Tris-HCl (pH 8.0), and 0.15% (w/v) 
Sarkosyl. KOD buffer (10-fold concentrated) consisted of 1200 mM Tris-HCl, 15 
mM MgSO4, 100 mM KCl, 60 mM (NH4)2SO4, 1% v/v Triton-X 100 and 1 mg/mL 
BSA 
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Sample preparation: Serum (stored at -80°C in 100 µL aliquots), was thawed in a 25°C 
water bath for 10 minutes, then stored on ice prior to sample dilution.  Samples were 
mixed by gentle vortexing for 8 seconds.  A 6% serum sample solution was prepared by 
dilution into 0.94× SB17 supplemented with 0.6 mM MgCl2, 1 mM trisodium EGTA, 0.8 
mM AEBSF, and 2 µM Z-Block.  A portion of the 6% serum stock solution was diluted 
10-fold in SB17 to create a 0.6% serum stock. 6% and 0.6% stocks are used to detect 
high- and low-abundance analytes, respectively.   
Capture reagent (SOMAmer) and streptavidin plate preparation: SOMAmers were 
grouped into 2 mixes according to the relative abundance of their cognate analytes. 
Stock concentrations were 4 nM in each SOMAmer, and the final concentration of each 
SOMAmer was 0.5 nM. SOMAmer stock mixes were diluted 4-fold in SB17 buffer, 
heated to 95 °C for 5 min and cooled to 37°C over a  15 minute period prior to use. This 
denaturation-renaturation cycle is intended to normalize SOMAmer conformer 
distributions and thus ensure reproducible SOMAmer activity in spite of variable 
histories.  Streptavidin plates were washed twice with 150 µL buffer PB1 prior to use.  
Equilibration and plate capture: Heat-cooled 2× SOMAmer mixes (55 µL) were 
combined with an equal volume of 6% or 0.6% serum dilutions, producing equilibration 
mixes containing 3% and 0.3% serum. The plates were sealed with a Silicone Sealing 
Mat (Axymat Silicone sealing mat, VWR) and incubated for 1.5 h at 37 °C. Equilibration 
mixes were then transferred to the wells of a washed 96-well streptavidin plate and 
further incubated on an Eppendorf Thermomixer set at 37 °C, with shaking at 800 rpm, 
for two hours. 
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Manual Assay: Unless otherwise specified, liquid was removed by dumping, followed 
by two taps onto layered paper towels. Wash volumes were 150 µL and all shaking 
incubations were done on an Eppendorf Thermomixer set at 25 °C, 800 rpm.  
Equilibration mixes were removed by pipetting, and plates washed twice for 1 minute 
with buffer PB1 supplemented with 1 mM dextran sulfate and 500 µM biotin, then 4 
times for 15 seconds with buffer PB1. A freshly made solution of 1 mM NHS-PEO4-
biotin in buffer PB1 (150 µL /well) was added, and plates incubated for 5 minutes with 
shaking. The NHS-biotin solution was removed, and plates washed 3 times with buffer 
PB1 supplemented with 20 mM glycine, and 3 times with buffer PB1. Eighty-five µL of 
buffer PB1 supplemented with 1 mM DxSO4 were then added to each well, and plates 
were irradiated under a BlackRay UV lamp (nominal wavelength 365 nm) at a distance 
of 5 cm for 20 minutes with shaking. Samples were transferred to a fresh, washed 
streptavidin-coated plate, or an unused well of the existing washed streptavidin plate, 
combining high and low sample dilution mixtures into a single well. Samples were 
incubated at room temperature with shaking for 10 minutes. Unadsorbed material was 
removed and the plates washed 8 times for 15 seconds each with buffer PB1 
supplemented with 30% glycerol. Plates were then washed once with buffer PB1. 
SOMAmers were eluted for 5 minutes at room temperature with 100 µL CAPSO elution 
buffer. 90 µL of the eluate was transferred to a 96-well HybAid plate and 10 µL 
neutralization buffer was added.   
Semi-Automated Assay: Streptavidin plates bearing adsorbed equilibration mixes 
were placed on the deck of a BioTek EL406 plate washer, which had been programmed 
to perform the following steps: unadsorbed material is removed by aspiration, and wells 
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are washed 4 times with 300 µL of buffer PB1 supplemented with 1 mM dextran sulfate 
and 500 µM biotin. Wells are then washed 3 times with 300 µL buffer PB1. One hundred 
fifty µL of a freshly prepared (from a 100 mM stock in DMSO) solution of 1 mM NHS-
PEO4-biotin in buffer PB1 is added. Plates are incubated for 5 minutes with shaking. 
Liquid is aspirated, and wells were washed 8 times with 300 µL buffer PB1 
supplemented with 10 mM glycine. One hundred µL of buffer PB1 supplemented with 1 
mM dextran sulfate are added. After these automated steps, plates were removed from 
the plate washer and placed on a thermoshaker mounted under a UV light source 
(BlackRay, nominal wavelength 365 nm) at a distance of 5 cm for 20 minutes. The 
thermoshaker was set at 800 rpm and 25 °C. After 20  minutes irradiation, samples were 
manually transferred to a fresh, washed streptavidin plate (or to an unused well of the 
existing washed plate). High-abundance (3% serum + 3% aptamer mix) and low-
abundance reaction mixes (0.3% serum + 0.3% aptamer mix) were combined into a 
single well at this point.  This “Catch-2” plate was placed on the deck of BioTek EL406 
plate washer, which had been programmed to perform the following steps: the plate was 
incubated for 10 minutes with shaking. Liquid is aspirated, and wells are washed 21 
times with 300 µL buffer PB1 supplemented with 30% glycerol. Wells are washed 5 
times with 300 µL buffer PB1, and the final wash is aspirated. One hundred µL CAPSO 
elution buffer are added, and SOMAmers are eluted for 5 minutes with shaking. 
Following these automated steps, the plate was then removed from the deck of the 
plate washer, and 90 µL aliquots of the samples were transferred manually to the wells 
of a HybAid 96-well plate that contained 10 µL neutralization buffer. 
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Hybridization to custom Agilent 8× 15k microarrays: 24 µL of the neutralized eluate 
were transferred to a new 96-well plate and 6 µL of 10× Agilent Block (Oligo 
aCGH/ChIP-on-chip Hybridization Kit, Large Volume, Agilent 5188-5380), containing a 
set of hybridization controls composed of 10 Cy3 SOMAmers was added to each well.  
Thirty µL  2× Agilent Hybridization buffer were added to each sample and mixed.  Forty 
µL of the resulting hybridization solution were manually pipetted into each “well” of the 
hybridization gasket slide (Hybridization Gasket Slide, 8-microarray per slide format, 
Agilent).  Custom Agilent microarray slides, bearing 10 probes per array complementary 
to 40 nucleotide random region of each SOMAmer with a 20× dT linker, were placed 
onto the gasket slides according to the manufacturers’ protocol.  The assembly 
(Hybridization Chamber Kit – SureHyb-enabled, Agilent) was clamped and incubated for 
19 hours at 60 °C while rotating at 20 rpm.  
Post Hybridization Washing: Approximately 400 mL Agilent Wash Buffer 1 was 
placed into each of two separate glass staining dishes.  Slides (no more than two at a 
time) were disassembled and separated while submerged in Wash Buffer 1, then 
transferred to a slide rack in a second staining dish also containing Wash Buffer 1.  
Slides were incubated for an additional 5 minutes in Wash Buffer 1 with stirring.  Slides 
were transferred to Wash Buffer 2 pre-equilibrated to 37°C and incubated for 5 minutes 
with stirring. Slides were transferred to a fourth staining dish containing acetonitrile, and 
incubated for 5 minutes with stirring. 
Microarray Imaging: Microarray slides were imaged with an Agilent G2565CA 
Microarray Scanner System, using the Cy3-channel at 5 µm resolution at 100% PMT 
setting, and the XRD option enabled at 0.05.  The resulting TIFF images were 
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processed using Agilent feature extraction software version 10.5.1.1 with the 
GE1_105_Dec08 protocol. 
 
Luminex probe design:  Probes immobilized to beads bore 40 
deoxynucleotides complementary to the 3’ end of the 40 nucleotide random 
region of the target SOMAmer. The SOMAmer complementary region was 
coupled to Luminex Microspheres through a hexaethyleneglycol (HEG) linker 
bearing a 5’ amino terminus. Biotinylated detection deoxyoligonucleotides 
consisted of 17-21 deoxynucleotides complementary to the 5’ primer region of 
target SOMAmers. Biotin moieties were appended to the 3’ ends of detection 
oligos. 
Coupling of probes to Luminex Microspheres:  Probes were coupled to 
Luminex Microplex Microspheres essentially per the manufacturer’s instructions, 
but with the following modifications:  amino-terminal oligonucleotide amounts 
were 0.08 nMol per 2.5×106 microspheres, and the second EDC addition was 5 
µL at 10 mg/mL. Coupling reactions were performed in an Eppendorf 
ThermoShaker set at 25°C and 600 rpm. 
Microsphere hybridization: Microsphere stock solutions (about 40000 
microspheres/µL) were vortexed and sonicated in a Health Sonics ultrasonic 
cleaner (Model: T1.9C) for 60 seconds to suspend the microspheres. Suspended 
microspheres were diluted to 2000 microspheres per reaction in 1.5× TMAC 
hybridization solutions and mixed by vortexing and sonication. Thirty-three µL per 
reaction of the bead mixture were transferred into a 96-well HybAid plate. Seven 
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µL of 15 nM biotinylated detection oligonucleotide stock in 1× TE buffer were 
added to each reaction and mixed. Ten µL of neutralized assay sample were 
added and the plate was sealed with a silicon cap mat seal. The plate was first 
incubated at 96 °C for 5 minutes and incubated at 5 0 °C without agitation 
overnight in a conventional hybridization oven. A filter plate (Dura pore, Millipore 
part number MSBVN1250, 1.2 µm pore size) was prewetted with 75 µL 1× TMAC 
hybridization solution supplemented with 0.5% (w/v) BSA. The entire sample 
volume from the hybridization reaction was transferred to the filter plate. The 
hybridization plate was rinsed with 75 µL 1× TMAC hybridization solution 
containing 0.5% BSA and any remaining material was transferred to the filter 
plate. Samples were filtered under slow vacuum, with 150 µL buffer requiring 
about 8 seconds to evacuate. The filter plate was washed once with 75 µL 1× 
TMAC hybridization solution containing 0.5% BSA and the microspheres in the 
filter plate were resuspended in 75 µL 1× TMAC hybridization solution containing 
0.5% BSA. The filter plate was protected from light and incubated on an 
Eppendorf Thermalmixer R for 5 minutes at 1000 rpm. The filter plate was then 
washed once with 75  µL 1× TMAC hybridization solution containing 0.5% BSA. 
75  µL of 10 µg/mL streptavidin phycoerythrin (SAPE-100, MOSS, Inc.) in 1× 
TMAC hybridization solution was added to each reaction and incubated on 
Eppendorf Thermalmixer R at 25°C at 1000 rpm for 60  minutes. The filter plate 
was washed twice with 75  µL 1× TMAC hybridization solution containing 0.5% 
BSA and the microspheres in the filter plate were resuspended in 75  µL 1× 
TMAC hybridization solution containing 0.5% BSA. The filter plate was then 
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incubated protected from light on an Eppendorf Thermalmixer R for 5 minutes, 
1000 rpm. The filter plate was then washed once with 75  µL 1× TMAC 
hybridization solution containing 0.5% BSA. Microspheres were resuspended in 
75 µL 1× TMAC hybridization solution supplemented with 0.5% BSA, and 
analyzed on a Luminex 100 instrument running XPonent 3.0 software. At least 
100 microspheres were counted per bead type, under high PMT calibration and a 
doublet discriminator setting of 7500 to 18000. 
QPCR read-out: Standard curves for qPCR were prepared in water ranging from 
108 to 102 copies with 10-fold dilutions and a no-template control.  Neutralized 
assay samples were diluted 40-fold into diH2O. The qPCR master mix was 
prepared at 2× final concentration (2× KOD buffer, 400 µM dNTP mix, 400 nM 
forward and reverse primer mix, 2× SYBR Green I and 0.5 U KOD EX). Ten µL of 
2× qPCR master mix was added to 10  µL of diluted assay sample. qPCR was 
run on a BioRad MyIQ iCycler with 2 minutes at 96 °C followed by 40 cycles of 
96 °C for 5 seconds and 72 °C for 30 seconds. 
Pull-down assay:  Pull-down assays were performed as described previously3. 
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Figure Legends 
 
Figure 1. Aptamer-based assay reagent and assay principles. The 
primary analyte capture reagent and quantified component consists of an 
analyte-specific aptamer coupled to a Cy3 moiety and a biotin group joined to 
the fluorophore-substituted aptamer through a photocleavable linker (Panel 
A). The principal features of the assay consist of equilibration of capture 
reagent and analyte mixture in solution, followed by immobilization of the 
entire capture reagent population on immobilized streptavidin through the 
biotin moieties of the capture reagent population. The immobilized capture 
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reagent population, including analyte/capture reagent complexes, is washed 
to remove non-complexed proteins. Immobilized protein analytes are then 
biotinylated using a conventional amine-reactive biotinylation reagent. The 
entire capture reagent population, including biotinylated analyte/capture 
reagent complexes, is then released into solution via photocleavage. 
Biotinylated analyte/capture reagent complexes are exclusively captured on 
immobilized streptavidin via the biotin moieties appended to the analyte 
population. Washes remove the capture reagent population at large, leaving 
only analyte/capture reagent complexes. The remaining capture reagent 
population is a surrogate for the analyte/capture reagent population. This 
material is eluted from immobilized analytes and quantified via conventional 
DNA quantification methods.  
 
Figure 2. Diagram of manual plate-based assay steps and dose-
response curves generated in manual plate-based assay format. The five 
steps of the manual plate-based assay - equilibration, biotinylation, 
photocleavage, and elution, are punctuated by three wash-and-dump cycles 
and one liquid transfer. The total processing time is about 70 minutes (Panel 
A). A set of dose response curve generated in a nine-plex manual assay 
format at various capture reagent concentrations (Panel B). Dose-response 
curves were generated by spiking analytes into plasma at the indicated 
concentrations. Shown are resistin and MCP-1.  Dose-response curves of 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
64
2.
1 
: P
os
te
d 
8 
Ju
l 2
01
0
MIP-4, RANTES, MMP-9, MMP-7, Lipocalin 2, tPA, and IL-8 can be found in 
Supplemental Materials.   
 
Figure 3.  Precision profiles and limits of quantification of plate- and 
bead-based assays.  Eight individual measurements of fluorescent signal as 
a function of analyte concentration in buffer were made for each of nine 
analytes in multiplexed format. For the dose-response curves (left of each 
panel), the average RFU at each concentration is denoted by the blue 
markers and the eight individual measurements used to compute each 
average are denoted by the red markers plotted on the four parameter curve 
fit (solid blue line). Precision profiles (right of each panel) were computed with 
two different methods: (1) by calculating the variance in computed 
concentrations (blue, bottom left of each panel) and (2) by calculating the 
variance in log RFU (assay response, top right of each panel) combined with 
the slope of the standard curve (red). Panels A, C, and E were generated in 
plate-based format. Panels B, D, and F were generated in bead-based 
format. Analytes measured were MCP-1 (Panels A and B), MMP9 (Panel C 
and D), resistin (Panels E and F) tPA (Supplemental Figure 1B), MMP-7 
(Supplemental Figure 1B), IL-8 (Supplemental Figure 1A), Lipocalin 2 
(Supplemental Figure 1A), MIP-4 (Supplemental Figure 1A), Protein S 
(Supplemental Figure 1B) and RANTES (Supplemental Figure 1B). 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
64
2.
1 
: P
os
te
d 
8 
Ju
l 2
01
0
 Figure 4. High-resolution titration of analytes. Analytes were titrated in 
20% concentration increments in the region of signal generated by serum 
without spikes. Assay eluates were quantified by Luminex bead hybridization. 
 
Figure 5.  Differential expression between case and control populations. 
Twenty-four case samples and twenty-four control samples were measured 
using the model 9-plex plate-based assay.  Empirical CDFs were constructed 
for the control (blue) and case (red) populations separately for each analyte 
and are displayed in panels a-i.  Spikes into the control samples (tPA, MMP-
9, and Lipocalin 2) result in clear “down-regulation”, spikes into case samples 
(IL-8, MCP-1, resistin and RANTES) result in clear “up-regulation” and the 
two analytes not spiked (MIP-4 and MMP-7) show no differential expression. 
 
Supporting Figure Legends 
 
Supporting Figure 1.  Demonstration of aptamer specificity by pull-down 
assay. SOMAmers were incubated with target proteins, plasma, or target 
proteins spiked into plasma for 45 minutes. Protein/SOMAmer complexes were 
captured on magnetic streptavidin beads (MyOne C1), washed, and then treated 
with a mixture of NHS-biotin and NHS-AlexaFluor 647. Protein/SOMAmer 
complexes were photocleaved from beads and a portion fractionated on SDS 
gels (first set of 3 lanes, marked “equilibrium”). Protein/SOMAmer complexes 
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were then adsorbed to monomeric avidin  agarose beads, washed, and then 
eluted with 2 mM biotin in SB17.  Complexes were captured a third time onto 
magnetic streptavidin beads (MyOne C1) substituted with a bound biotinylated-
primer complementary to the 3’ fixed region of the SOMAmer.  Not all SOMAmer 
complexes can be captured onto these beads since the 3’ fixed regions of 
SOMAmers are sometimes inaccessible for annealing while bound to the target 
protein (as evident in the gels for MMP-7 and MMP-9).  The complexes were 
eluted by increasing the pH to 12, and then neutralized. Portions were 
fractionated on SDS gels (second set of 3 lanes).  Shown are purified target 
protein spiked into buffer (lanes 1), purified target protein spiked into 10% plasma 
(lanes 2), and 10% plasma with no spike (lanes 3).   
 
Supporting Figure 2.  Precision profiles and limits of quantification of plate- 
and bead-based assays.  Eight individual measurements of fluorescent signal 
as a function of analyte concentration in buffer were made for each of nine 
analytes in multiplexed format. For the dose-response curves (left of each panel), 
the average RFU at each concentration is denoted by the blue markers and the 
eight individual measurements used to compute each average are denoted by 
the red markers plotted on the four parameter curve fit (solid blue line). Precision 
profiles (right of each panel) were computed with two different methods: (1) by 
calculating the variance in computed concentrations (blue, bottom left of each 
panel) and (2) by calculating the variance in log RFU (assay response, top right 
of each panel) combined with the slope of the standard curve (red). Left-hand 
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panels were generated in plate-based (SOMAPanel) format. Right-hand panels 
were generated in bead-based (SOMAscan) format.  
 
Supporting Figure 3. qPCR readout of plate-based assay eluates. Portions of 
samples generated in the experiment for Table 2 were diluted and assayed by 
qPCR per Materials and Methods.  
 
Supporting Figure 4.  Minimum multiplex capacity of plate-based assay 
platforms. Sixty-one SOMAmers recognizing analytes identified as biomarkers 
on the bead-based SOMAScan platform were combined. Serum was added at 
0.011%, 0.035%, 0.11%, 0.35%, 1.1%, 3.45%, 10.9%, and 34.5% v/v, and 
analyte signal measured as described in Materials and Methods. The log of the 
ratio of analyte signal at 10.9% and 0.011% was calculated, and plotted as a 
cumulative distribution function. Analyte signals at 10.9% serum are elevated at 
least 2.8-fold over those at 0.011% serum for all sixty-one biomarkers.   
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Tables 
 
Table 1. Comparison of automated bead-based Discovery-plex and plate-
based SOMAPanel assay formats. 
 
Metric Bead-based Discovery 
Assay 
Plate-based SOMAPanel 
Targeted Assay 
Partitioning Method (Capacity) Catch 1 – SA Agarose Beads 
(>1000-plex) 
Catch 1 & 2 – SA plates 
(~200-plex) 
Up-front Prep (Time) Bead prep (~30 minutes) 
Robotic setup 
None 
Post-equilibration processing 
time 
~150 minutes ~50 minutes 
Throughput 96 samples/day/FTE 384 samples/day/FTE 
Manual operation Yes Yes 
Average LLOQ <1  pM <2pM 
Coefficient of variation ~5% ~7% 
Automation instrumentation Biomek FX with modifications Stock BioTek EL406 plate 
washer 
 
 
 
Table 2. Comparison of slide-based and bead-based read-out formats. 
 
 
Lower Limit of 
Quantification (pM) 
Upper Limit of 
Quantification (pM) 
Quantification Range 
(logs) 
Analyte Agilent Luminex Agilent Luminex Agilent Luminex 
IL-8 0.32 0.5 210 240 2.8 2.7 
MIP-4 0.66 2.0 3,600 1000,000 3.8 5.7 
Lipocalin-2 0.83 0.78 260 1,500 2.5 3.3 
MCP-1 1.2 1.8 700 1,500 2.8 3.9 
RANTES 1.8 3.5 420 360 2.4 2.0 
MMP-7 1.9 6.8 550 1,100 2.5 2.2 
resistin 1.4 1.8 1,900 4,400 3.1 3.4 
MMP-9 1.6 5.4 13,000 19,000 3.9 3.5 
tPA 1.2 3.2 1,300 1,400 3.1 2.7 
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